Gilead Sciences, Inc. (GILD)
After hours:
| Previous close | 82.39 |
| Open | 81.95 |
| Bid | 82.78 x 400 |
| Ask | 82.82 x 100 |
| Day's range | 81.57 - 83.17 |
| 52-week range | 62.07 - 87.87 |
| Volume | |
| Avg. volume | 6,960,280 |
| Market cap | 103.098B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 100.99 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (3.72%) |
| Ex-dividend date | 13 Sept 2024 |
| 1y target est | N/A |
- Business Wire
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
FOSTER CITY, Calif., September 12, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV). There were 2 incident cases among 2,180 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir
- Business Wire
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
FOSTER CITY, Calif. & BURLINGAME, Calif., September 10, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
- Business Wire
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
FOSTER CITY, Calif., September 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place Sept. 7-10, 2024 in San Diego, Calif. Data to be highlighted across three oral presentations include: initial results from two cohorts of the EVOKE-02 study of Trodelvy® (sacituzumab govitecan-hziy
